Summary It is the industry analysis specialist’s new report, “Pulmonary Arterial Hypertension (PAH) - Drug Pipeline Analysis and Market Forecasts to 2016"" is an essential source of information and analysis on the global PAH market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global PAH market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global PAH sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by its team of industry experts. Scope The scope of the report includes: - Annualized global PAH market revenues data from 2005 to 2009, forecast forward for seven years to 2016. - Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. - Pipeline analysis data provides a split across different phases, mechanism of actions being developed and emerging trends. Key classes of mechanism of action include endothelin receptor antagonists, platelet aggregation inhibitors, phosphodiesterase inhibitors, serotonin pathway antagonists, angiotensin receptor antagonists, P2Y 12 receptor inhibitors, PDE5 inhibitors, prostacyclin (PGI2) agonists, nitric oxide synthetase inhibitors. - Analysis of the current and future market competition in the global PAH market. Key market players covered are Actelion Ltd.,United Therapeutics Corporation, Bayer AG, Gilead Sciences, Pfizer Inc., Novartis AG, Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly and Company, Lung RX and GlaxoSmithKline Plc. - Insightful reviews of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with PAH. For more information, please visit : http://www.aarkstore.com/reports/Pulmonary-Arterial-Hypertension-PAH-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-37972.html Or email us at press@aarkstore.com or call +919272852585 Aarkstore Enterprise Tel : +912227453309 Mobile No: +919272852585 Email : contact@aarkstore.com Website : http://www.aarkstore.com Blog: http://blogs.aarkstore.com/ Follow us on twitter: http://twitter.com/aarkstoredotcom
Related Articles -
Pulmonary, Arterial, Hypertension, Drug, Pipeline, Analysis, Market, Forecasts, Pulmonary Arterial Hypertension, Drug Pipeline Analysis, Market,
|